Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan

Objective: To evaluate drug-drug interactions (DDIs) between gefitinib or erlotinib with fluoxetine, and/or losartan. Methods: Human pooled microsomes, supersomes, and cryopreserved human hepatocytes were used to monitor DDIs in vitro. RED (Rapid Equilibrium Dialysis) protein binding was employed to...

Full description

Bibliographic Details
Main Authors: Thu-Lan T. Luong, Michael J. McAnulty, David L. Evers, Brian J. Reinhardt, Peter J. Weina
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Current Research in Toxicology
Subjects:
Drug-Drug Interaction
Erlotinib
Gefitinib
Fluoxetine
Losartan
Cytochrome P450
Online Access:http://www.sciencedirect.com/science/article/pii/S2666027X21000232

Internet

http://www.sciencedirect.com/science/article/pii/S2666027X21000232

Similar Items